AllDocs -> cancers

Screening for Thyroid Disorders and Thyroid Cancer in Asymptomatic Adults C HAPTER 51 By Marie-Dominique Beaulieu Page 2 Screening for Thyroid Disorders and 51 Thyroid Cancer in Asymptomatic Adults Prepared by Marie-Dominique Beaulieu, MD, MSc, FCFP 1 drawing from materials prepared for the U.S. Preventive Services Task Force 2 A s in 1 990,< 1 > the Canadian Task Force on the Periodic Health Examination has concluded that there is not enough evidence to recommend the inclusion of screening for thyroid dysfunction (hyperthyroidism and hypothyroidism) in asymptomatic adults. The effectiveness of screening for thyroid cancer has also been poorly evaluated so that neither inclusion nor ...

Page 2 Thyroid cancer in England 1996 to 2004. A geographical profile of mortality. Authors: Michael Goldacre, David Yeates, Leicester Gill, Myfanwy Griffith, Henry McGuinness, Daniel Meddings Published by: Unit of Health-Care Epidemiology, Oxford University, and South East England Public Health Observatory, 2005 This document provides a geographical profile of mortality from thyroid cancer in England. The geographical areas covered are the standard local authority areas of England. The period covered is January 1 1996 to December 31 2004. The data are analysed from mortality files supplied to the Public Health Observatories by the Office for National Statistics. This analysis includes mortality data about males and females of all ages. The maps, charts and tables show both-sexes-combined and sex-specific results, including standardised mortality ratios (SMRs). ...

B.C. Cancer Agency Protocol Summary HNTSH_20may05 Page 1 of 2 PRINT DATE: 30/05/2005 10:44 AM BCCA Protocol Summary for Radioiodine Imaging in Patients with Thyroid Cancer using Thyrotropin Alpha Protocol Code HNTSH Tumour Group Head and Neck Contact Physician Dr. John Hay ELIGIBILITY: patients with thyroid cancer who have had either radioactive iodine ablation of post- operative thyroid remnants or treatment of metastatic disease patients who are not being prepared for radioactive iodine therapy significant morbidity after thyroxine withdrawal in the past patient is aware that thyrotropin is a less effective preparation for iodine scanning than thyroxine withdrawal used in patients who are unable to mount an adequate endogenous TSH response to thyroid hormone withdrawal (eg, hypopituitarism) EXCLUSIONS: ...

1672 Main St. Ste. E #264 • Ramona, CA 92065 • Tel: 760.789.8928 • Fax: 760.789.8929 • Toll Free: 800.475.1955 • www.proteinbiotechnologies.com HUMAN THYROID CANCER TISSUE ARRAY Catalog Number: TMA-136 Each three (3) dots from three different tissue spots represents one single specimen that was selected and pathologically confirmed Cases: 63 Cores: 63 Diameter: 1.5mm Thickness: 5 µm Standard IHC: Tg confirmed Layout : 7 x 9 1 2 3 4 5 6 7 8 9 A 1 2 3 4 5 6 7 8 9 B 10 11 12 13 14 15 16 17 18 C 19 20 21 22 23 24 25 26 27 D 28 29 30 31 32 33 34 35 36 E 37 38 ...

ThyCa: Thyroid Cancer Survivors’Association,Inc. SM An all-volunteer non-profit 501 (c)(3) organization of thyroid cancer survivors, family members, and health professionals, dedicated to education, communication, support, awareness for early detection, and thyroid cancer research fundraising and research grants. P.O. Box 1545, New York, NY 10159-1545 www.thyca.org Toll Free 1-877-588-7904 thyca@thyca.org Tax ID # 52-2169434 Thyroid Cancer Facts • Thyroid cancer is the most common endocrine cancer . Thyroid cancer is a cancerous tumor or growth located within the thyroid gland. • Thyroid cancer is one of the few cancers that has increased in incidence rates over the past several years. There are expected to be 17% more new cases in 2006 than in 2005 in the United States. • The American Cancer Society estimates that there will be about 30,180 new cases of ...

About Thyroid Cancer • Thyroid cancer is the most common endocrine cancer . • It occurs in all age groups, mainly adults. It affects about three times as many women as men. • There are several types—papillary, follicular, medullary, anaplastic, and variants. • Thyroid cancer is one of the few cancers that is increasing in incidence— with 17% more new cases in 2006 than in 2005. It's #1 in incidence growth in women and #3 in men. • About 30,180 people, including 22,590 women and 7,590 men, will be diagnosed with thyroid cancer in 2006 in the United States, according to the American Cancer Society. About 870 women and 630 men (1,500 total) will die of thyroid cancer in 2006. Signs to discuss with your physician • You feel a lump in your neck, or your doctor may notice a nodule in your neck during a routine checkup. Most of these thyroid nodules are benign ...

thyroid cancer 1186 DATASET FOR THYROID CANCER HISTOPATHOLOGY Surname Forenames. Date of birth Sex. Hospital. Hospital no. NHS no. Date of receipt.. Date of reporting.... Report no. Pathologist. Surgeon. Specimen type Thyroidectomy Total Near total Not stated Lobectomy Right Left Not stated Total Near total Isthmus Biopsy/resection of metastasis (Define site) Gross description of thyroid specimen Location of carcinoma(s) Right lobe Left lobe ...

ThyCa: Thyroid Cancer Survivors’ Association, Inc . www.thyca.org thyca@thyca.org Order Form-ThyCa Spirit Items We are pleased to offer you these unique items for your use or for great gifts! Proceeds support ThyCa’s services, outreach, and thyroid cancer research. SPIRIT ITEM Each Quantity Total LOGO PIN The beautiful ThyCa Spirit Pin (tie tack style) features the ThyCa logo in cloisonné 5.00 T-SHIRT 100% preshrunk cotton, Light gray with ThyCa’s colorful logo Circle S M L XL XXL XXXL 12.00 POLO SHIRT 100 % preshrunk cotton, extra heavyweight jersey, welt collar and cuffs, 3-button placket with wood tone buttons. Light Grey. ThyCa’s colorful logo embroidered on it. Available in size M only 16.00 TOTE BAG Made with 600 denier polyester; zippered top opening, front pockets, ...

DIABETES THYROID CANCER ADDISON’S DISEASE EDUCATIONAL / INFORMATIONAL ORDERING NEUROMUSCULAR THYROID Page 2 Your Source for Sensitive Autoimmune Diagnostics The Company — Commitment to Excellence The Company — Commitment to Excellence KRONUS ® , the pioneer and market leader in sensitive thyroid autoimmune diagnostics, was founded in 1986 with a mission to provide unique and innovative products with superior performance standards to the medical industry. Working in partnership with several of the world’s leading research and developmental scientists, we continue to focus our efforts on offering highly-sensitive and specific diagnostic assays to aid in the diagnosis and monitoring of various endocrine and metabolic disorders. More than a dozen test kits are ...

President: Aldo Pinchera, Department of Endocrinology, University of Pisa, Italy Chairperson: Furio Pacini, Section of Endocrinology and Metabolism, University of Siena, Italy International Congress on Thyroid Cancer Management Siena, Italy May 30-31 2006 Endorsed and organised under the auspices of the ETA Siena Invite 30/1/06 16:50 Page 1 Page 2 T uesday 30th May 9.30-9.45 Registration 9.45-1 0.00 Opening ceremony 1 0.00-1 2.00 Thyroid cancer : background G Epidemiological review of thyroid cancer G Prognostic classification of (P ap) thyroid cancer G U pdated pathology of thyroid cancer G Thyroid cancer and iodine intake G Thyroid cancer registr ...

1672 Main St. Ste. E #264 • Ramona, CA 92065 • Tel: 760.789.8928 • Fax: 760.789.8929 • Toll Free: 800.475.1955 • www.proteinbiotechnologies.com HUMAN THYROID CANCER TISSUE ARRAY Catalog Number: TMA-078 Each dot represents a DISEASED tissue spot from one individual specimen that was selected and pathologically confirmed Cases: 80 Cores: 80 Diameter: 1.5mm Thickness: 5 µm Standard IHC: Thyroglobulin(TG) antibody confirmed Layout : 8 x 10 1 2 3 4 5 6 7 8 9 10 A 1 2 3 4 5 6 7 8 9 10 B 11 12 13 14 15 16 17 18 19 20 C 21 22 23 24 25 26 27 28 29 30 D 31 32 33 34 35 36 37 ...

10 ENDOCRINE NEWS • NOVEMBER 2005 COVER STORY: TRI-POINT SERIES The incidence of thyroid cancer has been rising gradually over the past decade. After initial treat- ment with thyroidectomy, usually followed by adjuvant radioiodine ablation and thyroid hormone suppressive therapy, most patients will be cured and remain cancer free. However, persistent or recur- rent disease is not uncommon. Drs. Tuttle and Mazzaferri discuss the rapidly evolving approaches to detect thyroid cancer recurrence, and the therapeutic challenges posed by the increased sensitivity of these new surveillance modalities. Current therapies are ineffective for those patients who have metastatic cancer unresponsive to surgery and radioiodine. Dr. Fagin discusses how the knowledge of the genetic origin of thyroid cancer is being used to design and test promising new therapies. From The Endocrine Society’s Research ...

NYCRIS Regional Audit The Management of Thyroid Cancer Steering Group Meeting Blackwell Grange Hotel, Darlington, 3:00 p.m., 18 th July 2001 Present: Dr S Atkin, Consultant Endocrinologist, Hull Royal Infirmary Dr C Bennett, Projects Manager, Information Services, NYCRIS Dr C Coyle, Consultant Clinical Oncologist, Cookridge Hospital Mr J England, Consultant ENT Surgeon, Hull Royal Infirmary Dr J Hardman, Consultant Clinical Oncologist, South Cleveland Hospital Mrs C Ingham, The British Thyroid Foundation Mr M Lansdown, Consultant Surgeon, St James’s University Hospital Dr U Mallick (Chairperson), Consultant Clinical Oncologist, Northern Centre for Cancer Treatment Mrs R Tate, Projects Co-ordinator, Information Services, NYCRIS Apologies: Miss P Durning, Consultant Surgeon, South Cleveland Hospital Dr S Gilby, Consultant Endocrinologist, ...

Thyroid cancer is the most common endocrine-related cancer ; however, it is rare compared to other cancers. In the United States there are only about 20,000 new patients annually. Even though the diagnosis of cancer is terrifying, the outlook for patients with thyroid cancer is usually excellent. First, most thyroid cancer is easily curable with surgery. Second, thyroid cancer rarely causes pain or disability. Third, effective and well-tolerated treatment is available for the most common forms of thyroid cancer . Cancer of the Thyroid 1 SYMPTOMS ADDITIONAL PATIENT RESOURCES WWW. THYROID .ORG For further details on this and other thyroid -related topics, please visit the patient resources section on the American Thyroid Association website at www. thyroid .org What are the symptoms of thyroid cancer ? The ...

Management of Management of Thyroid Cancer Thyroid Cancer Sajani Shah MD Sajani Shah MD November 18, 2005 November 18, 2005 SUNY Downstate SUNY Downstate Morbidity and Mortality Morbidity and Mortality Conference Conference Page 2 Thyroid Embryology Thyroid Embryology Derived from endodermal Derived from endodermal tissue at base of tongue tissue at base of tongue Embryonal remnants form Embryonal remnants form Thyroglossal duct; pyramidal Thyroglossal duct; pyramidal lobe; lingual thyroid lobe; lingual thyroid Fuse with C Fuse with C - - cells (neural cells (neural crest origin), derived from crest origin), derived from the ...

Thyroid Cancer Recurrence - Wally Patching Memorial Lecture – May ‘05 Canadian Thyroid Cancer Support Group (Thry’vors) Inc. www.thryvors.org 1 Thyroid Cancer Recurrence Wally Patching Memorial Lecture, May 15, 2005 given by Irving B. Rosen, M.D. In 2004, the Board of Directors of the Canadian Thyroid Cancer Support Group (Thry'vors) Inc . announced the creation of the annual Wally Patching Memorial Lecture to honour one of our most vibrant and determined founding members and to help contribute to his vision of improved Canadian thyroid cancer patient information, support and access to qualified thyroid cancer specialists. The first memorial lecture was given on May 14th, 2005 in Ottawa by Dr. Irving B. Rosen. Wally was diagnosed with a rare and aggressive variant of papillary thyroid cancer in 1998 at age 58. At the time of his diagnosis, his cancer ...

ThyCa Annual Report for 2004 www.thyca.org 1 ThyCa: Thyroid Cancer Survivors’ Association, Inc. www.thyca.org • 1-877-588-7904 • thyca@thyca.org Annual Report for 2004 Organization Overview ThyCa: Thyroid Cancer Survivors' Association, Inc.<www.thyca.org> is a national, all-volunteer non-profit 501(c)(3) organization of thyroid cancer survivors, family members, and health care professionals. ThyCa is dedicated to support, education, and communication for thyroid cancer survivors, their families, and friends, as well as awareness and outreach to health care professionals and the public. ThyCa’s Tax ID #52-2169434 . Board of Directors, December 2004 These are the members of ThyCa’s all-volunteer leadership and management team: Gary Bloom, Chair, Maryland Sara Gorrell Brenner, Virginia Leah Guljord, Assistant Chair, Florida ...

ADDITIONAL PATIENT RESOURCES WWW. THYROID .ORG For further details on this and other thyroid -related topics, please visit the patient resources section on the American Thyroid Association website at www. thyroid .org 1 SYMPTOMS What is thyroid cancer and its symptoms? Thyroid cancer is the most common endocrine-related cancer .The outlook for patients with thyroid cancer is excellent in that safe and effective therapy is available in most cases.A lump (nodule) in the thyroid is the key sign of its presence.Most thyroid cancers do not cause any symptoms,and only rarely do they cause pain,difficulty in swallowing,or hoarseness. CAUSES What causes thyroid cancer ? Thyroid cancer is more common in people who have a history of exposure of the thyroid gland to radiation,have a family history of thyroid cancer ,and are older than 40 years ...

Investigation of Excess Thyroid Cancer Incidence in Los Alamos County Final Report Prepared by William F. Athas, PhD Division of Epidemiology, Evaluation, and Planning New Mexico Department of Health April 1996 This study was supported by funds from the Office of Epidemiology and Health Surveillance, U.S. Department of Energy; Grant No. DE-FG04-91AL75237. Page 2 ACKNOWLEDGMENTS The author would like to extend thanks to the members of the Thyroid Cancer Technical Steering Sub Committee for their helpful comments and criticisms (Scott Davis, PhD; Earl Ford, MD; Frank Gilliland, MD; Don Morris, MD; Gerry Petersen, PhD; and Helen Stanbro; MS); to Michael Jackson, MD at the Los Alamos Medical Center for valuable discussions regarding thyroid surgery; to George Voelz, MD; and Laurie Wiggs, PhD, at the Los Alamos National Laboratory ...

Prognosis of Papillary Thyroid Cancer Päivi Siironen Helsinki 2005 Page 2 prognosis of papillary thyroid cancer päivi siironen department of surgery university of helsinki helsinki, finland Academic Dissertation To be presented with the permission of the Medical Faculty of the University of Helsinki, for public examination in the Auditorium 3, Meilahti Hospital, Haartmaninkatu 4, on December 5th 2005, at 12 noon. Page 3 Supervised by Docent Caj Haglund Department of Surgery University of Helsinki Docent Reijo Haapiainen Department of Surgery University of Helsinki Reviewed by: Docent Johanna Arola Department of Pathology University of Helsinki Docent Erkki Nylamo Department of Surgery University of Turku Discussed with: Docent ...

Canadian Thyroid Cancer Support Group (Thry’vors) Inc. 2005 www.thryvors.org 1 Thry’vors Canadian Thyroid Cancer Support Group (Thry’vors) Inc. Thyroid Cancer Resource List This list was produced by Thry’vors to help thyroid cancer patients’ locate information about the disease. Included is information on books, articles, online resources and organizations that you may find useful. The information contained on this list does not constitute medical advice. Users are encouraged to work closely with their doctors to make sure that their individual medical needs are met. The Canadian Thyroid Cancer Support Group (Thry'vors) Inc . does not endorse any product, treatment, service or practitioner and is not responsible for the quality of the information or services offered by other resources, organizations or websites. Last updated: October 2005 ...

Thyroid Cancer Clinic - Papillary/Follicular Cancer Papillary/Follicular Cancer Papillary/Follicular Cancer : Papillary and follicular cancer , or carcinoma, account for about 80-85% of all thyroid malignancies. They get their names from their appearance under the microscope. Some are pure papillary, some are purely follicular in nature, and some are mixed, that is, both types of cancer cells may be present in the same tumor. In fact, some of these tumors are actually referred to as “follicular variant of papillary carcinoma”. The important thing to understand is that 1) the typical forms of these cancers are quite curable in a very large percentage of cases and, 2) they behave in somewhat dissimilar ways, and affect slightly different age groups, though there are often exceptions to the rule. Papillary carcinoma is more common in the younger age groups, though ...

Decreased expression of haemoglobin beta (HBB) gene in anaplastic thyroid cancer and recovory of its expression inhibits cell growth M Onda * ,1 , J Akaishi 1 , S Asaka 1 , J Okamoto 1 , S Miyamoto 1 , K Mizutani 1 , A Yoshida 2 , K Ito 3 and M Emi 1 1 Department of Molecular Biology, Institute of Gerontology, Nippon Medical School, Kawasaki, Japan; 2 Kanagawa Prefectural Cancer Center, Department of Surgery, Kanagawa, Japan; 3 Ito Hospital, Tokyo, Japan Anaplastic thyroid cancer (ATC) is one of the most fulminant and foetal diseases in human malignancies. However, the genetic alterations and carcinogenic mechanisms of ATC are still unclear. Recently, we investigated the gene expression ...

What You Need To Know About Thyroid Cancer NATIONAL INSTITUTES OF HEALTH National Cancer Institute ™ What You Need To Know About Index Page 2 This booklet is about thyroid cancer . The Cancer Information Service can help you learn more about this disease. The staff can talk with you in English or Spanish. The number is 1–800–4– CANCER (1–800–422–6237). The number for deaf and hard of hearing callers with TTY equipment is 1–800–332–8615. The call is free. Este folleto es acerca del cáncer de tiroides. Llame al Servicio de Información sobre el Cáncer para saber más sobre esta enfermedad. Este servicio tiene personal que habla español. El número a llamar es el 1–800–4– CANCER (1–800–422–6237). Personas con problemas de ...

European Medicines Agency Pre-authorisation Evaluation of Medicines for Human Use 7 Westferry Circus, Canary Wharf, London, E14 4HB, UK Tel. (44-20) 74 18 84 00 Fax (44-20) 75 23 70 40 E-mail: orphandrugs@emea.eu.int www.emea.eu.int EMEA 2004 Reproduction and/or distribution of this document is authorised for non-commercial purposes only provided the EMEA is acknowledged Document Date: London, 5 November 2004 EMEA/COMP/136/04 COMMITTEE FOR ORPHAN MEDICINAL PRODUCTS PUBLIC SUMMARY OF POSITIVE OPINION FOR ORPHAN DESIGNATION OF 2-Methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl) ethenyl]-phenol for the treatment of anaplastic thyroid cancer On 14 April 2004, orphan designation (EU/3/04/195) was granted by the European Commission to David Chaplin, United Kingdom, for 2-Methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl) ethenyl]-phenol (combretastatin A4 phosphate) for ...

Reference Section a report by Er nest L Mazzaferri , MD , MACP President-Elect, American Thyroid Association (ATA) Types and Basic Biologic Features of Thyroid Cancer Differentiated Thyroid Cancer Thyroid cancer is the most common endocrine malignancy. It comprises several distinct tumor types; including papillary thyroid cancer (PTC); follicular thyroid cancer (FTC); and Hürthle cell thyroid cancer (HTC), which are tumors of the thyroid follicular cell derived from the embryonic foregut. They ordinarily concentrate iodine and sometimes synthesize and secrete thyroid hormone, and for this reason are collectively referred to as differentiated thyroid cancer (DTC).The three tumor types represent 80%, 11%, and 3% of all thyroid cancers, respectively, and have 10-year mortality ...

187 Burden of Suffering Thyroid cancer accounts for an estimated 14,000 new cancer cases and more than 1,000 deaths in the U.S. each year. 1 The annual incidence is about 4/100,000 population. 2 Women account for 77% of new cases and 61% of deaths. 1 Current overall 5-year survival with treatment is 95% in whites and 90% in blacks, 1 but is much lower with some histologic types (e.g., medullary, anaplastic). 3–5 Among those at substantially increased risk for thyroid cancer are persons exposed to external upper body (especially head and neck) irradiation during infancy or childhood, and individuals with a family history of thyroid cancer or multiple endocrine neoplasia type 2 (MEN 2) syndrome. 6–10 The risk of radiation-induced thyroid nodu- larity and cancer increases with radiation dose ...

THYROID Volume 11, Number 8, 2001 Mary Ann Liebert, Inc. Susceptibility of Thyroid Cancer Cells to 7-Hydroxystaurosporine–Induced Apoptosis Correlates with Bcl-2 Protein Level Su He Wang, Ellen Phelps, Saho Utsugi, and James R. Baker, Jr. 7-Hydroxystaurosporine (UCN-01) is a selective protein kinase C (PKC) inhibitor and is being developed as a novel anticancer agent. Because of reports that PKC may be involved in the pathogenesis of some forms of thy- roid cancers, we examined four thyroid carcinoma lines (FRO, KAT5, NPA, and WRO). These cells were found to have different susceptibility to UCN-01 treatment, and there appeared to be a correlation between UCN- 01–induced death and expression levels of endogenous Bcl-2. KAT5 cells, which normally express a low amount of Bcl-2, exhibited significantly higher sensitivity to UCN-01–induced death than the other cell lines. Of inter- est, susceptibility ...

November, 2002 This Report Contains: • Thyroid Cancer Incidence by Age Group and Gender. • Thyroid Cancer Incidence by Gender and Race. • Thyroid Cancer Cases by Stage at Diagnosis and Gender. • Thyroid Cancer Survival Probabilities. • Thyroid Cancer Risk Factors. The Ohio Cancer Incidence Surveillance System Cancer of the thyroid made up about one percent (625 cases) of the invasive cancers diagnosed in Ohio in 1999 and reported to the Ohio Cancer Incidence Surveillance System (OCISS) (Table 1). For 1999, the Ohio age-adjusted thyroid cancer incidence rate was 5.5 cases per 100,000 residents, which is 24 percent less than the age-adjusted 1999 U.S. rate of 7.2 per 100,000 residents. Completeness of reporting of invasive thyroid cancer is estimated ...

National Cancer Institute SEER Program 120 THYROID T iny and usually insignificant carcinomas can be found in five to 10% or more of all thyroid glands that are carefully examined under the microscope at autopsy, but relatively few of them grow or spread to produce symptoms that lead to their detection during a person’s lifetime. The thyroid cancers that are diagnosed each year represent about 1% of all cancers in the U.S. population. Most types of thyroid cancer rank quite high in terms of successful treatment and long term survival. However, some rare subtypes may have a poor prognosis. The highest incidence rates for thyroid cancer in the SEER regions occur in women, particularly in the Pacific Island and Southeast Asian populations living in California and Hawaii. The rates are highest among Filipino women (14.6 per ...